Medigene announced a $1M milestone payment from Regeneron (REGN) was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy Bio’s (TSVT) pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics of Regeneron’s MAGE-A4 cell therapy, which contains a Medigene generated T cell receptor targeting MAGE-A4e
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- SPY ETF Update, 11/27/2024
- QQQ ETF Update, 11/26/2024
- Intellia announces FDA granted RMAT designation to nexiguran ziclumeran
- VOO ETF Update, 11/25/2024
- FDA posts observations from previous Regeneron facility inspection
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
